贝伐珠单抗联合FOLFIRI化疗方案治疗结直肠癌肺转移的效果  

Effect of Bevacizumab Combined with FOLFIRI Chemotherapy in the Treatment of Lung Metastasis of Colorectal Cancer

作　　者：王尚 赵小勇[1] WANG Shang;ZHAO Xiaoyong(The Fourth District of General Surgery Department,Jiaozuo People's Hospital,Jiaozuo 454002,Henan,China)

机构地区：[1]河南省焦作市人民医院普通外科四区,河南焦作454002

出　　处：《中国药物滥用防治杂志》2025年第1期99-101,113,共4页Chinese Journal of Drug Abuse Prevention and Treatment

基　　金：河南省医学科技攻关联合共建项目立项目(编号:LHGJ20221008)。

摘　　要：目的:研究贝伐珠单抗、伊立替康、亚叶酸钙和FOLFIRI联合化疗对于晚期转移性结直肠癌(mCRC)病患的效果。方法:收集2020年3月—2022年8月我院接诊的132例结直肠癌并伴有肺转移患者,按照随机数字表法将患者分成研究组与对照组,每组66例。观察组接受FOLFIRI化疗加贝伐珠单抗的治疗,而对照组则仅进行FOLFIRI化疗。比较两组疾病控制率、肿瘤标志物、血管内皮功能指标、不良反应。结果:观察组疾病控制率为高于对照组(P<0.05);观察组治疗后血清癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、表皮生长因子受体(EGFR)、胰岛素样生长因子-1(IGF-1)水平均低于对照组(P<0.05);观察组治疗后血清一氧化氮(NO)、血管性血友病因子(vWF)水平均高于对照组,内皮素(ET)水平低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:mCRC肺转移患者采用贝伐珠单抗和FOLFIRI化疗方案治疗可以有效提升疾病控制效果,降低血清肿瘤标志物,延长生存期。Objective:To study the effect of bevacizumab,irinotecan,calcium folinate and FOLFIRI combined chemotherapy on patients with advanced metastatic colorectal cancer(mCRC).Methods:A total of 132 patients with colorectal cancer and pulmonary metastasis admitted to our hospital from March 2020 to August 2022 were collected.The patients were divided into study group and control group according to the random number table method,with 66 patients in each group.The observation group received FOLFIRI chemotherapy plus bevacizumab,while the control group only received FOLFIRI chemotherapy.The disease control rate,tumor markers,vascular endothelial function indexes and adverse reactions were compared between the two groups.Results:The disease control rate of the observation group was higher than that of the control group(P<0.05).After treatment,the levels of serum carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),epidermal growth factor receptor(EGFR)and insulin-like growth factor-1(IGF-1)in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of serum nitric oxide(NO)and von Willebrand factor(vWF)in the observation group were higher than those in the control group,and the level of endothelin(ET)was lower than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Bevacizumab and FOLFIRI chemotherapy can effectively improve the effect of disease control,reduce serum tumor markers and prolong survival in patients with mCRC lung metastasis.

关 键 词：转移性结直肠癌 贝伐单抗 FOLFIRI方案 肿瘤标志物 疾病控制率 不良反应 

分 类 号：R735.34[医药卫生—肿瘤]